Eradicating HIV-1 infection: seeking to clear a persistent pathogen.
Effective antiretroviral therapy (ART) blunts viraemia, which enables HIV-1-infected individuals to control infection and live long, productive lives. However, HIV-1 infection remains incurable owing to the persistence of a viral reservoir that harbours integrated provirus within host cellular DNA. This latent infection is unaffected by ART and hidden from the immune system. Recent studies have focused on the development of therapies to disrupt latency. These efforts unmasked residual viral genomes and highlighted the need to enable the clearance of latently infected cells, perhaps via old and new strategies that improve the HIV-1-specific immune response. In this Review, we explore new approaches to eradicate established HIV-1 infection and avoid the burden of lifelong ART.
Department of Medicine, University of North Carolina at Chapel Hill.
Nancie M
NM
Archin
Department of Medicine, University of North Carolina at Chapel Hill.
Julia Marsh
JM
Sung
Department of Medicine, University of North Carolina at Chapel Hill.
Carolina
C
Garrido
Department of Medicine, University of North Carolina at Chapel Hill.
Natalia
N
Soriano-Sarabia
1] Department of Medicine, University of North Carolina at Chapel Hill. [2] Department of Microbiology and Immunology, University of North Carolina at Chapel Hill. [3] Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
David M
DM
Margolis
D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002460:Cell Line; D060740:Disease Eradication / Q000379:methods*; D004195:Disease Models, Animal; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D014766:Viremia; D016662:Virus Integration; D017735:Virus Latency / Q000502:physiology*
D019380:Anti-HIV Agents